Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Michael Parini sold 4,250 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $179.11, for a total transaction of $761,217.50. Following the completion of the transaction, the executive vice president now directly owns 39,253 shares in the company, valued at approximately $7,030,604.83. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Michael Parini also recently made the following trade(s):
- On Friday, May 3rd, Michael Parini sold 1,622 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $172.06, for a total transaction of $279,081.32.
Vertex Pharmaceuticals stock opened at $176.01 on Friday. The stock has a 50 day moving average price of $175.38. The stock has a market capitalization of $45.78 billion, a P/E ratio of 62.19, a P/E/G ratio of 2.59 and a beta of 1.43. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $151.80 and a fifty-two week high of $195.81.
Institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in Vertex Pharmaceuticals by 19.3% during the first quarter. FMR LLC now owns 24,434,159 shares of the pharmaceutical company’s stock valued at $4,494,663,000 after purchasing an additional 3,951,050 shares in the last quarter. Norges Bank purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $380,584,000. BlackRock Inc. grew its position in Vertex Pharmaceuticals by 2.9% during the first quarter. BlackRock Inc. now owns 20,176,298 shares of the pharmaceutical company’s stock valued at $3,711,428,000 after purchasing an additional 568,488 shares in the last quarter. GQG Partners LLC purchased a new position in Vertex Pharmaceuticals during the first quarter valued at approximately $94,444,000. Finally, Marshall Wace North America L.P. grew its position in Vertex Pharmaceuticals by 58.4% during the first quarter. Marshall Wace North America L.P. now owns 792,007 shares of the pharmaceutical company’s stock valued at $145,690,000 after purchasing an additional 291,952 shares in the last quarter. 94.94% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently issued reports on the stock. Goldman Sachs Group raised shares of Lenovo Group from a “neutral” rating to a “buy” rating in a research note on Thursday, May 23rd. They noted that the move was a valuation call. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Swann cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.40 price objective on the stock. in a research note on Tuesday, March 19th. They noted that the move was a valuation call. William Blair reaffirmed a “market perform” rating on shares of aTyr Pharma in a research note on Tuesday, March 26th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, June 2nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seventeen have given a buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus target price of $204.36.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: Derivative
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.